Nevia Bio (formerly Gina Life), a Haifa, Israel-based company developing a machine learning empowered platform for early detection of women’s health indications, raised $3M in Seed funding.
The round, which brought the total amount to $5M, included MindUP Digital Health Incubator and additional existing investors and was joined by Pitango HealthTech, Alive Israel HealthTech Fund and the Technion investment arms.
The funding will be used to support the company’s clinical trials in ovarian cancer, and to expand its pipeline to additional indications in women’s health space, in addition to enhancing the company’s data science capabilities.
Led by Dr. Inbal Zafir-Lavie and Dr. Shlomit Yehudai-Reshef, Nevia provides a platform that decodes information from women’s vaginal secretions by applying machine learning tools to identify specific proprietary biomarkers signatures to detect the disease in its early and late stages. The use of a biofluid and a scientific approach will enable the detection of women’s related diseases. Specifically, a simple vaginal swab will be collected from women, proprietary protein panel will be measured which will enable detection of ovarian cancer.
Since commencing activity in 2020, Nevia has conducted clinical trials, established a biobank of more than 900 samples of vaginal secretions from women of different populations and diseases. This novel biobank is linked to a digital database and enables the company to apply Machine Learning tools on the data collected, and to identify specific features characterizing patients, which can be used to detect, and potentially manage the disease.
FinSMEs
30/08/2023